The US bladder cancer market is estimated to grow modestly at a CAGR of around 9.7% during the forecast period. The US contributes significantly to the growth of the bladder cancer treatment market in North America. The increasing aging population across the country is augmenting the growth of the market. According to the American Cancer Society, bladder cancer occurs mainly in older people, with an average age at the time of diagnosis being 73 years. US Census Bureau estimated that people aged over 65 years represent around 15% of the total population of the country in 2015. This share is further estimated to reach 21% by 2030 and 24% by 2060.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-bladder-cancer-market
Bladder cancer is the fourth most common cancer in men; however, it is less common in women. American Cancer Society has provided bladder cancer statistics for 2019 in the US. The society estimates that around 80,470 new cases of bladder cancer will be diagnosed in the country, of which 61,700 will be in men and 18,770 will be in women. This prevalence of bladder cancer will lead to mortalities across the country. The US consists of some of the key players of the bladder cancer market such as Merck & Co, Inc., Pfizer, Inc., and Spectrum Pharmaceuticals, Inc., which further augments the growth of the market in the country.
US bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy.
The companies which are contributing to the growth of the US bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Johnson & Johnson Services, Inc., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc., and Spectrum Pharmaceuticals, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in April 2019, Johnson & Johnson Services, Inc.’s drug Balversa became the first targeted therapy for bladder cancer after an FDA approval for patients with mutations in the FGFR gene. Balversa (erdafitinib) is the first drug in the class to reach the US market. The FDA granted accelerated approval for the drug in patients with FGFR-mutated locally advanced or metastatic urothelial carcinoma (mUC) who have previously been treated with platinum-based chemotherapy and seen their disease progress.
US Bladder Cancer Market- Segmentation
By Cancer Type
- Transitional Cell Bladder Cancer/ Urothelial Carcinoma
- Squamous Cell Bladder Cancer
- Adenocarcinoma
- Others (Sarcomas, Carcinoma in Situ)
By Diagnosis
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (IVP)
- Others (Biomarkers)
By Treatment
- Surgery
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Others (Targeted Therapy)
A full report of US Bladder Cancer Market is available at: https://www.omrglobal.com/industry-reports/us-bladder-cancer-market
